LLY

Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
NRAS, KRAS, Eli Lilly and Company, LLY, AACR, Conference, NYSE, HRAS, Pharmaceutical industry, Vaccine

INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston.

Key Points: 
  • INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston.
  • These programs are among the next slate of new oncology agents planned to enter clinical trials for Loxo@Lilly in 2024.
  • "These new programs represent years of focused work to create differentiated molecules against exacting target product profiles.
  • Details on poster presentations are below:
    Presentation Title: Preclinical characterization of orally bioavailable, highly potent pan-KRAS inhibitors with selectivity over HRAS and NRAS

Lilly Announces Leadership Transitions

Retrieved on: 
Wednesday, October 4, 2023
Mason, Gilead Sciences, Jonsson, Gastroenterology, Diabetes, Stanford University, Neuroscience, Leigh, Tirzepatide, Inflammation, LLY, Dermatology, MD, Patient, Rheumatology, Eli Lilly and Company, Growth, NYSE, Pharmaceutical industry, Management, Obesity, Lilly

INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team.

Key Points: 
  • INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team.
  • Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.
  • Patrik Jonsson will assume leadership of Lilly Diabetes and Obesity as executive vice president and president, effective January 1, 2024, in addition to his current responsibility as executive vice president and president of Lilly USA.
  • A 33-year Lilly veteran with strong US and international commercial experience, Jonsson also has led Lilly Immunology and Lilly Bio-Medicines, as well as served as the general manager of Lilly Sweden, Scandinavia, Italy and Japan.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vericity, Inc. (Nasdaq - VERY), POINT Biopharma Global, Inc. (Nasdaq - PNT), Blue Apron Holdings, Inc. (Nasdaq - APRN), Chico’s FAS, Inc. (NYSE - CHS)

Retrieved on: 
Tuesday, October 3, 2023
Agreement, IA, Tripura Merger Agreement, Brodsky, PDL BioPharma, Blue Apron, LLY, Eli Lilly and Company, Sycamore Partners, NYSE

BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Agreement, Blue Apron will be acquired by Wonder Group (“Wonder”) for $13.00 per share in cash for each share of Blue Apron held.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease

Retrieved on: 
Friday, September 22, 2023
Hypersensitivity, Medical Affairs Bureau, Kidney failure, University, Chronic kidney disease, Hospital, EGFR, Glomerular filtration rate, Diabetes, Diabetic ketoacidosis, Angioedema, History, Kidney disease, Dialysis, Tablet, Boehringer Ingelheim, Transplant, Prednisone, Excipient, LLY, Polycystic kidney disease, Translational Health Science and Technology Institute, HIV disease progression rates, Patient, Risk, University of Washington Medical Center, Eli Lilly and Company, Region, Research, FDA, EMPA, CKD, III, News, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Dietary supplement, Pharmaceutical industry, Medicine

Jardiance is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.

Key Points: 
  • Jardiance is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.
  • "The meaningful benefits that empagliflozin demonstrated in the EMPA-KIDNEY phase III trial are welcome news for adults living with CKD in this country."
  • EMPA-KIDNEY was a large trial designed to reflect the broad range of adults with CKD with or without type 2 diabetes.
  • *Kidney disease progression: Defined as end-stage kidney disease (the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decline in estimated glomerular filtration rate (eGFR) to below 10 mL/min/1.73 m2, kidney death or a sustained decline of at least 40% in eGFR from randomization).

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

Retrieved on: 
Wednesday, September 13, 2023
China Biologic Products, IBN, Injection, Plaque, Asthma, NVS, Therapy, Dermis, AMD, University Medical Center, Hook effect, I&I, 3D, European Medicines Agency, COVID-19, Clinical trial, Infection, Inflammation, IL-17A, Psoriasis, EMA, VHH, LLY, UCB, Novartis, Patient, Lilly, Risk, Max Planck Institute for Multidisciplinary Sciences, Brussels Stock Exchange, UMG, Mab, CCL20, CXCL1, AF, Research, Moonlake, NYSE, Max Planck Society, Skin, Autoimmunity, Disease, Pharmaceutical industry, Vaccine

JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.

Key Points: 
  • Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-vivo animal study results anticipated in early 2024
    JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.
  • These results suggest NanoAbs’ therapeutic potential to relieve symptoms of plaque psoriasis.
  • Research shows that targeting IL-17F isoform in addition to IL-17A provides higher efficacy in treating plaque psoriasis.
  • Scinai recently started to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for plaque psoriasis to evaluate the effective dose and schedule of treatment, with in-vivo animal studies anticipated in early 2024.

Thinking about trading options or stock in C3.ai Inc, Eli Lilly And Co, Ambarella Inc, Advanced Micro Devices, or Sunrun Inc?

Retrieved on: 
Wednesday, August 30, 2023
RUN, AI, LLY, Report, Wall Street, AMD, AMBA, Retail

NEW YORK, Aug. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AI, LLY, AMBA, AMD, and RUN.

Key Points: 
  • NEW YORK, Aug. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AI, LLY, AMBA, AMD, and RUN.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report – Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement

Retrieved on: 
Tuesday, July 25, 2023
Eli Lilly and Company, LLY, Lilly, NYSE, Pharmaceutical industry

INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023.

Key Points: 
  • INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023.
  • Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay will also be available on the website following the conference call.

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

Retrieved on: 
Tuesday, July 25, 2023
Biotechnology, Pharmaceutical, Health, Chronic kidney disease, Hospital, Quality of life, Multimedia, SGLT2, Kidney, European Commission, Boehringer Ingelheim, Kidney disease, LLY, Risk, HR, Eli Lilly and Company, EC, CKD, NYSE, Pharmaceutical industry, EU

The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),8 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

Key Points: 
  • The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),8 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.
  • Cardio-renal-metabolic conditions affect over 1 billion people worldwide.7
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230718878355/en/
    “We celebrate this significant milestone in the field of chronic kidney disease.
  • CKD is a silent killer and prevention and early detection are crucial in the general population,” said Daniel Gallego, President of European Kidney Patients’ Federation.

2023 Humankind 100 List Announced Today

Retrieved on: 
Monday, July 24, 2023
Finance, Socially Responsible Investing, Environmental, Social and Governance (ESG), Banking, Professional Services, ADM, Food, Investment, Health, Internet, GOOGL, ABBV, PFE, Eli Lilly and Company, MRK, Quality of life, PG, Merck & Co., Social Security Government Pension Offset, NGO, AAPL, LLY, JNJ, Procter & Gamble, Microsoft, Water, MSFT, ESG, Johnson & Johnson, Social, AbbVie, Human, Risk management, Pharmaceutical industry, ADM (company), Biophysical environment, Apple, Pfizer

Humankind Investments , a quantitatively driven asset manager specializing in socially responsible investments, announced today the release of 2023’s “Humankind 100,” its annual ranking of the top U.S. companies offering the greatest benefit to humanity, based on Humankind Investments’ proprietary Humankind Value methodology.

Key Points: 
  • Humankind Investments , a quantitatively driven asset manager specializing in socially responsible investments, announced today the release of 2023’s “Humankind 100,” its annual ranking of the top U.S. companies offering the greatest benefit to humanity, based on Humankind Investments’ proprietary Humankind Value methodology.
  • “We launched the Humankind 100 with a two-fold purpose – to help people understand the companies best supporting their quality of life and to encourage companies to continue striving for progress,” said James Katz, founder and CEO of Humankind Investments.
  • The ranking was calculated using Humankind Investments’ proprietary Humankind Value methodology, which tends to favor companies that promote human health and improved quality of life.
  • “By publishing these rankings each year we’re optimistic that we can motivate companies to make progress on their own human impact.”

SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX

Retrieved on: 
Friday, July 21, 2023
Class Action Lawsuit, Professional Services, Legal, Eli Lilly and Company, LLY, NYSE, KSF, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .